Why Your Body Destroys NAD+ Before It Can Use It (And the $5 Fix Nobody Talks About)

Your body cannot use NAD+ directly. The molecule is too large to pass through a cell membrane, so when you swallow an NAD+ supplement or receive it through an IV, your body has to break it down into smaller pieces first, absorb those pieces, and then reassemble the full molecule inside the cell. That reassembly process happens through something called the salvage pathway, which is essentially a recycling system that takes NAD+ precursors and rebuilds them into usable NAD+ where it actually needs to be.

This is why IV NAD+ works the same way as oral NAD+. A 2019 pilot study tracked what happened during a 750 mg intravenous NAD+ infusion and found that the NAD+ was completely degraded in the bloodstream before any of it reached cells. Every milligram you inject gets broken apart first. The cell does not get NAD+. It gets the building blocks of NAD+, and then it builds.

Now, the most popular oral supplements, NMN and NR, are both precursors designed to enter this same salvage pathway. But there is an important detail about how they actually get in. NMN cannot enter most cells directly. It has to be converted to something called NR, which stands for nicotinamide riboside, before it can cross the membrane. This conversion is handled by an enzyme called CD73 on the cell surface. So whether you take NMN or NR, you are feeding the same entry point. They are not two different pathways. They are two different on-ramps to the same road.

That road gets more congested as you age.

There is an enzyme called CD38, which functions like a drain on your NAD+ supply. It consumes NAD+ as part of the immune signaling process, and it does its job regardless of whether your cells need that NAD+ for energy or repair. The problem is that CD38 activity increases roughly two to three fold across tissues as you get older, and research has found a near-perfect inverse relationship between CD38 activity and NAD+ levels. More CD38 means less NAD+. And because NMN and NR both feed the salvage pathway, they are trying to fill a bucket that is increasingly leaking from below.

This is the part that does not get discussed enough when people talk about NAD+ supplementation. The bottleneck is not necessarily absorption. The bottleneck is degradation.

But here is where the biology gets interesting. The salvage pathway is not the only way your body makes NAD+. There is a completely separate route called the Preiss-Handler pathway, and it uses a different starting material: nicotinic acid, which is the form of vitamin B3 most people know as niacin.

The Preiss-Handler pathway does not compete with CD38 the same way. It is running a different manufacturing line, and the end product is the same: NAD+ inside your cells.

A 2020 study in Cell Metabolism tested this directly in people with confirmed NAD+ deficiency caused by mitochondrial disease. Participants took 750 to 1000 milligrams of niacin per day, and after ten months, blood NAD+ had increased 2.3 times over baseline. Muscle NAD+, which is harder to raise because skeletal muscle is metabolically demanding tissue, increased 1.3 times. Alongside those numbers, the researchers saw improvements in muscle strength and markers of mitochondrial biogenesis, meaning the cells were not just accumulating more NAD+, they were doing more with it.

That 2.3x increase in blood NAD+ puts niacin in the same range as what the expensive precursors produce. And niacin costs about five dollars for a month's supply at any pharmacy.

There is one thing worth naming honestly. Niacin at these doses causes something called a niacin flush, where your skin turns red and warm, sometimes itchy, for twenty to thirty minutes after taking it. This happens because niacin triggers the release of prostaglandins, which are signaling molecules that dilate small blood vessels near the skin surface. It feels alarming the first time. It is not harmful, and it largely fades after the first two weeks as your body adapts. Starting with a lower dose and taking niacin with food reduces the intensity.

There is also an important distinction to make here. Niacinamide, which is another form of vitamin B3 also called nicotinamide, does not cause the flush and is widely available. But niacinamide feeds the salvage pathway, not the Preiss-Handler pathway. If you are buying niacin specifically to use the Preiss-Handler route, you need nicotinic acid, the version that flushes. The label matters.

One more layer worth adding. A 2019 study on NR supplementation in older adults found something unexpected: NR was partially converting to nicotinic acid inside the body, meaning it was feeding the Preiss-Handler pathway indirectly. This might explain some of the positive results seen with NR in studies. The NR you take does not stay NR. Some of it becomes niacin anyway. Which suggests that part of what you are paying for with NR is a slow, expensive delivery mechanism for something you could take directly.

The picture that emerges here is not that NMN and NR are useless. It is that they are operating inside a system with a significant degradation bottleneck, they are sharing an entry point, and they are using one pathway when there is another pathway available that bypasses the congestion entirely.

Most people spending forty or sixty dollars a month on NAD+ precursors do not know the Preiss-Handler pathway exists. The supplement industry has no financial incentive to tell them. Niacin has been off-patent for decades.

The biochemistry of NAD+ decline is real, and the logic of supplementing precursors is sound. But working harder against a leaky bucket is a different strategy than finding the other faucet.

---

References

1. Ratajczak J, Joffraud M, Trammell SAJ, et al. 2016. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications, 7:13103. Finding: NMN must be converted to NR by CD73 before cellular uptake, establishing NR as the common entry point for both NMN and NR supplementation. Source
2. Elhassan YS, Kluckova K, Fletcher RS, et al. 2019. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 287:1717-1728. Finding: NR supplementation produced significant increases in NAAD a Preiss-Handler pathway intermediate in human muscle, indicating NR partially converts to nicotinic acid in vivo. Source
3. Pirinen E, Auranen M, Khan NA, et al. 2020. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism, 316:1078-1090. Finding: Niacin 750-1000 mg/day raised blood NAD+ 2.3x and muscle NAD+ 1.3x in human subjects via the Preiss-Handler pathway, with concurrent improvements in muscle strength and mitochondrial biogenesis. Source
4. Grant R, Berg J, Mestayer R, et al. 2019. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 11:257. Finding: IV NAD+ 750 mg was rapidly and completely removed from plasma, with metabolites confirming full extracellular degradation before cellular uptake. Source
5. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. 2016. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 236:1127-1139. Finding: CD38 activity increases 2-3 fold with age across tissues, with near-perfect inverse correlation to NAD+ levels. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness